期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 25, 期 11, 页码 2160-2166出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2019.06.033
关键词
Allogeneic hematopoietic transplantation; HIV; Bone marrow
资金
- National Cancer Institute (NCI) [HHSN261200622012C-009]
- AMC through NCI [U01CA121947]
- National Heart, Lung, and Blood Institute [U10HL069294]
- NCI [K23CA177321-01A1]
We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV in a phase 11 prospective multicenter trial. The primary endpoint was 100-day nonrelapse mortality (NRM). Patients had an 8/8 HLA-matched related or at least a 7/8 HLA-matched unrelated donor. Indications for transplant were acute leukemia, myelodysplasia, and lymphoma. Conditioning was myeloablative or reduced intensity. There was no NRM at 100 days. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) was 41%. At 1 year, overall survival was 59%; deaths were from relapsed/progressive disease (n = 5), acute GVHD (n = 1), adult respiratory distress syndrome (n =1), and liver failure (n = 1). In patients who achieved complete chimerism, cell-associated HIV DNA and inducible infectious virus in the blood were not detectable. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据